Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Theravance Bio Ord (TBPH)
Theravance Bio Ord (TBPH)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Theravance Bio Ord UGLAND HOUSE SOUTH CHURCH STREET GEORGE TOWN E9 KY1-1104 CYM

www.theravance.com P: 650-808-6000

Description:

Theravance Biopharma is a biopharmaceutical company primarily focused on discovering, developing and commercializing respiratory medicines. The company was formed following the split of the erstwhile Theravance into two listed companies in June 2014 - Innoviva, Inc. (then Theravance, Inc.) and Theravance.'

Key Statistics

Overview:

Market Capitalization, $K 444,198
Enterprise Value, $K 146,028
Shares Outstanding, K 49,798
Annual Sales, $ 51,350 K
Annual Net Income, $ 872,130 K
Last Quarter Sales, $ 15,690 K
Last Quarter Net Income, $ -8,950 K
EBIT, $ -65,940 K
EBITDA, $ -62,900 K
60-Month Beta 0.36
% of Insider Shareholders 5.30%
% of Institutional Shareholders 99.10%
Float, K 47,159
% Float 94.70%
Short Volume Ratio 0.57

Growth:

1-Year Return -13.86%
3-Year Return -47.13%
5-Year Return -64.13%
5-Year Revenue Growth 233.66%
5-Year Earnings Growth 76.88%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.01 on 11/07/23
Latest Earnings Date 02/26/24
Earnings Per Share ttm -0.98
EPS Growth vs. Prev Qtr 39.29%
EPS Growth vs. Prev Year 19.05%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

TBPH Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -17.72%
Return-on-Assets % -11.83%
Profit Margin % 1,698.40%
Debt/Equity 0.00
Price/Sales 9.62
Price/Cash Flow N/A
Price/Book 1.89
Book Value/Share 4.66
Interest Coverage -13.57
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar